Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial

Gastroenterology

Volumn 104, Issue 5, 1993, Pages 1293-1301

  Singleton, John W ^a   Hanauer, Stephen B ^b   Gitnick, Gary L ^c   Peppercorn, Mark A ^d   Robinson, Malcolm G ^e   Wruble, Lawrence D ^f   Krawitt, Edward L ^g  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY OF OKLAHOMA   (United States)

^f Medical Center Plaza Memphis Tennessee USA ^*

^g UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; C REACTIVE PROTEIN; CREATININE; MESALAZINE;

ABDOMINAL PAIN; ADULT; ADVERSE DRUG REACTION; ARTICLE; CLINICAL TRIAL; COLON; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROHN DISEASE; DIARRHEA; DRUG DOSE; DRUG EFFICACY; DRUG SAFETY; DRUG THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PHARMACEUTICS; PHARMACOLOGY; PRIORITY JOURNAL; REMISSION; SMALL INTESTINE; SUSTAINED RELEASE PREPARATION; UREA NITROGEN BLOOD LEVEL; VOMITING;

ADOLESCENT; ADULT; AGED; AMINOSALICYLIC ACIDS; CAPSULES; CROHN DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMAN; MALE; MESALAMINE; MIDDLE AGE; PROSPECTIVE STUDIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TREATMENT OUTCOME;

EID: 0027218241     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/0016-5085(93)90337-C     Document Type: Article

References (20)

1. Sulfasalazine: pharmacology, clinical use, toxicity, and related new drug development
2. National Cooperative Crohn's Disease Study: results of drug treatment
3. National Cooperative Crohn's Disease Study: adverse reactions to study drugs
4. European Cooperative Crohn's Disease Study: results of drug treatment
5. Effect of sulfasalazine in patients with active Crohn's disease a controlled double-blind study
6. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease
7. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine
8. An experiment to determine the active therapeutic moiety of sulphasalazine
9. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis
10. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis
11. Topical and oral aminosalicylates
12. Clinical efficacy of oral mesalamine in Crohn's Disease
13. Effect of a slow-release 5-aminosalicylic acid preparation on disease activity in Crohn's disease
14. 5-aminosalicylic in the treatment of Crohn's disease. A 16-week, double-blind, placebo-controlled, multicenter study with Pentasa
15. Slow release 5-aminosalicyclic acid (Pentasa) for the treatment of active Crohn's disease
16. ® capsules in man
17. Radiographic findings of the National Cooperative Crohn's Disease Study
18. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI)
19. An index of inflammatory activity in patients with Crohn's disease
20. A simple index of Crohn's disease activity